Axsome Therapeutics

Turning patient needs into breakthrough discoveries.

[Axsome Therapeutics @axsome]

Axsome has had a tremendous start to 2026, including robust year-over-year growth for our commercial business, a recent FDA drug approval, and continued expansion and advancement of our industry-leading development pipeline.

Learn more here: https://t.co/p2FsB2xM47

[Axsome Therapeutics @axsome]

Today we initiated the CLARITY Phase 3 trial in adults with major depressive disorder with excessive daytime sleepiness symptoms as we continue to advance our innovative CNS pipeline.

Learn more here: https://t.co/RvuzA5HA4F

[Axsome Therapeutics @axsome]

Today we reported 4Q and full-year 2025 financial results highlighting the strong growth of our commercial products and advancement across our expanding CNS pipeline.

Learn more here: https://t.co/Tjt9E5XJTG

[Axsome Therapeutics @axsome]

We’re pleased to announce that the first patient has been dosed in the FORWARD Phase 3 trial of AXS-14 for the management of fibromyalgia, a chronic neurological pain condition where treatment options remain limited. Learn more here: https://t.co/8MeDJzvp6q

#fibromyalgia

[Axsome Therapeutics @axsome]

Our third quarter results highlight our continued commercial performance and execution across our innovative late-stage pipeline. Read more about our progress in today’s news release: https://t.co/8VtBwLSeAh

[Axsome Therapeutics @axsome]

Axsome Therapeutics has the honor of ringing today’s @NasdaqExchange Opening Bell in connection with its Frontiers in Brain Health R&D Day event being held today.

Learn more here: https://t.co/ekn4C8fKoj

#Nasdaq #OpeningBell

[Axsome Therapeutics @axsome]

We’re reporting earnings for the second quarter of 2025 on August 4, including a call with management to discuss these results and provide a business update. Learn more here: https://t.co/tiN1JSJpnE

[Axsome Therapeutics @axsome]

Join us at our Frontiers in Brain Health R&D Day for a look into our innovative CNS pipeline. Hear from physician thought leaders and the Axsome team discussing our current indications and clinical programs in #neurology and #psychiatry. Learn more here: https://t.co/oHh6lpATJ2

[Axsome Therapeutics @axsome]

During Alzheimer’s & Brain Awareness Month, we are encouraging people to prioritize brain health and share resources that could help people affected by Alzheimer’s disease and other CNS disorders.

Learn more here: https://t.co/JxGUcR9K7B

#AlzheimersAwareness

[Axsome Therapeutics @axsome]

Come and meet with our team at this year’s American Headache Society (@AHSheadache) Annual Meeting in Minneapolis where we’re sharing data from across our #migraine clinical program. Learn more about our presentations here: https://t.co/IvpFkfUdaH

#AHSAM #AHS25

[Axsome Therapeutics @axsome]

In honor of June’s Migraine and Headache Awareness Month theme, “Your Path to Better Days,” Axsome is sharing resources for patients and their loved ones affected by migraine.

Learn more about here: https://t.co/v2Dze3lWBQ

#MigraineAwareness #Migraine #MHAM2025

[Axsome Therapeutics @axsome]

We look forward to connecting with the sleep community this week at the APSS #SLEEP2025 conference in Seattle, where we will share data from our innovative research programs in narcolepsy and obstructive sleep apnea (OSA). Learn more here: https://t.co/Da6EazV2UU

[Axsome Therapeutics @axsome]

SYMBRAVO® (meloxicam and rizatriptan) is now available in the United States. Please see full Prescribing Information, including Boxed Warning, and the Medication Guide. Learn more here: https://t.co/YlZieaNlI9

[Axsome Therapeutics @axsome]

We’re presenting at @ASCPorg's Annual Meeting in Scottsdale this week. Please join us at our posters to meet the team and hear more about the presentations. Learn more here: https://t.co/XahZX8bUSm #ASCP2025

[Axsome Therapeutics @axsome]

We are proud to join @MentalHealthAm (MHA) and the broader mental health advocacy community to raise awareness and promote action during this year’s Mental Health Month. Learn more about how Axsome is taking action and find additional resources here: https://t.co/9RhETUDndr #MHAM

[Axsome Therapeutics @axsome]

Please join us at the 2025 AAN Annual Meeting where we have multiple presentations including pivotal Phase 3 results of the ACCORD-2 and SYMPHONY trials and a network meta-analysis of AXS-07 vs oral CGRPs. Learn more here: https://t.co/8jFRCD7id1 #AAN2025 #AANAM

[Axsome Therapeutics @axsome]

Today, we announced that the FOCUS Phase 3 trial of solriamfetol in adults with ADHD achieved its primary and key secondary endpoints. Learn more here: https://t.co/AsZP4NHN9e #ADHD

[Axsome Therapeutics @axsome]

The primary endpoint was achieved in the EMERGE Phase 3 trial in migraine patients experiencing inadequate response to oral CGRP inhibitors. Read here to learn more: https://t.co/cDriItqPtI

[Axsome Therapeutics @axsome]

Thank you, @bradloncar and @BiotechTVHQ for joining us at One World Trade today to discuss our 2024 accomplishments and our 2025 plans to advance our mission to deliver scientific breakthroughs patients living with serious CNS conditions:

[BiotechTV @BiotechTV]

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: With three approved products and filings for more over the near term, @axsome's CEO describes the scale and reach this company is building in the CNS space. $AXSM

Full video: https://t.co/FYeFCBpjJ2

[Axsome Therapeutics @axsome]

Today we announced positive results from the ENCORE long-term Phase 3 trial of AXS-12 in narcolepsy. Please read the full release for more details: https://t.co/OzMrWdT88Z #narcolepsy